ManRos Therapeutics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
ManRos Therapeutics General Information
Description
Operator of a biotechnology company intended to offer treatments against cystic fibrosis, neurodegenerative, and renal diseases. The company specializes in the research and development of small-molecule drugs against severe pathologies, such as solid tumors and leukemia, including polycystic kidney disease, enabling medical practitioners to get molecules at a reduced cost with the collaboration of industrial experts.
Contact Information
Website
www.manros-therapeutics.comCorporate Office
- LD Presqu'ile De Perharidy Building 1
- 29680 Roscoff
- France
Corporate Office
- LD Presqu'ile De Perharidy Building 1
- 29680 Roscoff
- France
ManRos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 01-Jun-2025 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 23-May-2017 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 15-Sep-2015 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 01-Jul-2014 | Completed | Startup | |||
| 3. Early Stage VC | 01-Jun-2011 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2008 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2007 | Completed | Startup |
ManRos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
ManRos Therapeutics Patents
ManRos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4268824-A1 | Imidazo[2,1-f][1,2,4]triazine derivatives useful as a medicament | Inactive | 26-Apr-2022 | ||
| AU-2020242304-A1 | Roscovitine analogues and use thereof for treating rare biliary diseases | Inactive | 20-Mar-2019 | ||
| CA-3133409-A1 | Roscovitine analogues and use thereof for treating rare biliary diseases | Pending | 20-Mar-2019 | ||
| EP-3941476-A2 | Roscovitine analogues and use thereof for treating rare biliary diseases | Active | 20-Mar-2019 | ||
| EP-3941476-B1 | Roscovitine analogues and use thereof for treating rare biliary diseases | Active | 20-Mar-2019 | A61K31/52 |
ManRos Therapeutics Signals
ManRos Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Agoranov | Accelerator/Incubator | Minority |
ManRos Therapeutics FAQs
-
When was ManRos Therapeutics founded?
ManRos Therapeutics was founded in 2007.
-
Where is ManRos Therapeutics headquartered?
ManRos Therapeutics is headquartered in Roscoff, France.
-
What is the size of ManRos Therapeutics?
ManRos Therapeutics has 5 total employees.
-
What industry is ManRos Therapeutics in?
ManRos Therapeutics’s primary industry is Biotechnology.
-
Is ManRos Therapeutics a private or public company?
ManRos Therapeutics is a Private company.
-
What is ManRos Therapeutics’s current revenue?
The current revenue for ManRos Therapeutics is .
-
How much funding has ManRos Therapeutics raised over time?
ManRos Therapeutics has raised $7.26M.
-
Who are ManRos Therapeutics’s investors?
Agoranov has invested in ManRos Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process